Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

doi:10.1182/blood-2017-04-779405

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Blood - 10 Aug 2017

Stein Eytan M, DiNardo Courtney D, Pollyea Daniel A, Fathi Amir T, Roboz Gail J, Altman Jessica K, Stone Richard M, DeAngelo Daniel J, Levine Ross L, Flinn Ian W, Kantarjian Hagop M, Collins Robert, Patel Manish R, Frankel Arthur E, Stein Anthony, Sekeres Mikkael A, Swords Ronan T, Medeiros Bruno C, Willekens Christophe, Vyas Paresh, Tosolini Alessandra, Xu Qiang, Knight Robert D, Yen Katharine E, Agresta Sam, de Botton Stephane, Tallman Martin S

Abstract excerpt

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes. This first-in-human phase 1/2 study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow

Share to Enzyme Inhibitors

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Maximum Tolerated Dose

Share to Neoplasm Recurrence, Local

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 28588020
DOI: 10.1182/blood-2017-04-779405
PMCID: PMC5572791

Genes

IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.PMID 28588020Read ↗

Enasidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Semantic proximity Read ↗

Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid LeukemiaSemantic proximity Read ↗

Targeting the IDH2 Pathway in Acute Myeloid Leukemia.Semantic proximity Read ↗

Enasidenib.Semantic proximity Read ↗

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.Semantic proximity Read ↗

Enasidenib: First Global Approval.Semantic proximity Read ↗

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.Semantic proximity Read ↗

IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.